Market Overview:
The global rapid-dissolving tablets market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of chronic diseases, rising geriatric population, and growing demand for convenience in drug delivery. Based on type, the global rapid-dissolving tablets market is segmented into anti-psychotics drugs, anti-epileptics drugs, and other types. The anti-psychotics drugs segment is expected to account for the largest share of the global rapid-dissolving tablets market in 2018. This segment is projected to grow at a CAGR of 7.8% during the forecast period from 2018 to 2030 due to increasing incidence of mental disorders such as schizophrenia and bipolar disorder across the globe. Based on application,the global rapid dissolving tabletmarketis divided into CNS diseases (central nervous system diseases), gastrointestinal diseases (gastrointestinal tract disorders), CV diseases (cardiovascular system disorders), and other applications including respiratory infections and pain management).
Product Definition:
A rapid-dissolving tablet (RDT) is a tablet that dissolves in the mouth within seconds, delivering medication to the patient quickly. RDTs are used when it is important for the medication to reach the patient quickly, such as in cases of heart attack or stroke.
Anti-Psychotics Drug:
Anti-psychotics drug is a new class of antipsychotic agent that has been in the market for about five years. It's major characteristics are its ability to minimize or eliminate positive symptoms and reduce the overall dose of anti-psychotic medication, which results in better control over mental illness.
Anti-Epileptics Drug:
Anti-epileptics drug is used to prevent seizures and/or to reduce the duration and severity of seizures. Anti-epileptic drugs are also used in treating certain types of epilepsy, but they do not cure the disease. The anti-epileptic drug class includes both new chemical entities as well as generic drugs with established therapeutic profiles.
Application Insights:
Based on application, the global market is segmented into CNS diseases, gastrointestinal diseases, cardiovascular/vasculitis diseases, chronic ulcers and diabetic foot ulcers, catheter-related infections (CRU), central venous catheter complications (CVCs), other dissolving drugs for rapid treatment of life-threatening conditions (ODTLCs), and others. The CNS disease segment dominated the overall market in terms of revenue in 2017 owing to high incidence rates of epilepsy and Alzheimer¢â‚¬â„¢s disease. According to WHO Epilepsy Fact Sheet 2016 & Alzheimer¢â‚¬â„¢s factsheet 2015 respectively there were approximately 50 million people suffering from epilepsy globally as well as 8.3 million people suffering from dementia worldwide. Furthermore, according to data published by CDC National Center for Health Statistics in 2018 regarding prevalence rate of diabetes among U.S.
Regional Analysis:
Asia Pacific is expected to be the fastest-growing region over the forecast period. The increasing prevalence of neurological, gastrointestinal, and cardiovascular disorders; rising awareness about mental health; and growing disposable income are some of the major factors contributing to market growth in Asia Pacific. In addition, increasing investments by manufacturers in this region for brand new product development will drive the market further. For instance, Otsuka Pharmaceutical Co., Ltd has been developing a new dissolving tablet called Fycompa Tablets which are used for treating schizophrenia (acquired) and bipolar disorder (mania). These tablets have an active ingredient called as lurasidone which is rapidly absorbed after oral administration through stomach or intestine resulting into rapid action within 30 minutes that lasts up to 12 hours.
In 2016, North America accounted for more than 25% of global revenue due to high treatment rates coupled with favorable reimbursement policies & healthcare expenditure levels in U.
Growth Factors:
- Increasing demand for convenience foods: The growing trend of busy lifestyles has led to an increased demand for convenient foods that can be consumed without having to spend too much time on preparation. Rapid-dissolving tablets fit this requirement perfectly and are thus expected to witness high growth in the coming years.
- Rising prevalence of chronic diseases: The incidence of chronic diseases such as diabetes and hypertension is on the rise globally, leading to an increased need for effective medication. Rapid-dissolving tablets offer a fast and convenient way of taking medication, making them a preferred choice among patients.
- Growing popularity of over-the-counter drugs: OTC drugs are becoming increasingly popular due to their ease of availability and affordability. Rapid-dissolving tablets are well suited for OTC medications as they offer quick relief from symptoms with minimal fuss or inconvenience involved in taking them orally.
Scope Of The Report
Report Attributes
Report Details
Report Title
Rapid-dissolving Tablets Market Research Report
By Type
Anti-Psychotics Drug, Anti-Epileptics Drug, Other
By Application
CNS Diseases, Gastrointestinal Diseases, CVS Diseases, Other
By Companies
Teva, Merck, Mylan, Pfizer, Johnson and Johnson, GSK, Otsuka, Eli Lilly and Company, AstraZeneca, Bristol-Myers Squibb, Teva
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
191
Number of Tables & Figures
134
Customization Available
Yes, the report can be customized as per your need.
Global Rapid-dissolving Tablets Market Report Segments:
The global Rapid-dissolving Tablets market is segmented on the basis of:
Types
Anti-Psychotics Drug, Anti-Epileptics Drug, Other
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
CNS Diseases, Gastrointestinal Diseases, CVS Diseases, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Teva
- Merck
- Mylan
- Pfizer
- Johnson and Johnson
- GSK
- Otsuka
- Eli Lilly and Company
- AstraZeneca
- Bristol-Myers Squibb
- Teva
Highlights of The Rapid-dissolving Tablets Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Anti-Psychotics Drug
- Anti-Epileptics Drug
- Other
- By Application:
- CNS Diseases
- Gastrointestinal Diseases
- CVS Diseases
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Rapid-dissolving Tablets Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Rapid-dissolving tablets are a type of medication that dissolve quickly in the mouth. They are used to treat a variety of conditions, including pain and inflammation.
Some of the major companies in the rapid-dissolving tablets market are Teva, Merck, Mylan, Pfizer, Johnson and Johnson, GSK, Otsuka, Eli Lilly and Company, AstraZeneca, Bristol-Myers Squibb, Teva.
The rapid-dissolving tablets market is expected to grow at a compound annual growth rate of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Rapid-dissolving Tablets Market Overview 4.1 Introduction 4.1.1 Market Taxonomy 4.1.2 Market Definition 4.1.3 Macro-Economic Factors Impacting the Market Growth 4.2 Rapid-dissolving Tablets Market Dynamics 4.2.1 Market Drivers 4.2.2 Market Restraints 4.2.3 Market Opportunity 4.3 Rapid-dissolving Tablets Market - Supply Chain Analysis 4.3.1 List of Key Suppliers 4.3.2 List of Key Distributors 4.3.3 List of Key Consumers 4.4 Key Forces Shaping the Rapid-dissolving Tablets Market 4.4.1 Bargaining Power of Suppliers 4.4.2 Bargaining Power of Buyers 4.4.3 Threat of Substitution 4.4.4 Threat of New Entrants 4.4.5 Competitive Rivalry 4.5 Global Rapid-dissolving Tablets Market Size & Forecast, 2018-2028 4.5.1 Rapid-dissolving Tablets Market Size and Y-o-Y Growth 4.5.2 Rapid-dissolving Tablets Market Absolute $ Opportunity
Chapter 5 Global Rapid-dissolving Tablets Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Rapid-dissolving Tablets Market Size Forecast by Type
5.2.1 Anti-Psychotics Drug
5.2.2 Anti-Epileptics Drug
5.2.3 Other
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Rapid-dissolving Tablets Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Rapid-dissolving Tablets Market Size Forecast by Applications
6.2.1 CNS Diseases
6.2.2 Gastrointestinal Diseases
6.2.3 CVS Diseases
6.2.4 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Rapid-dissolving Tablets Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Rapid-dissolving Tablets Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Rapid-dissolving Tablets Analysis and Forecast
9.1 Introduction
9.2 North America Rapid-dissolving Tablets Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Rapid-dissolving Tablets Market Size Forecast by Type
9.6.1 Anti-Psychotics Drug
9.6.2 Anti-Epileptics Drug
9.6.3 Other
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Rapid-dissolving Tablets Market Size Forecast by Applications
9.10.1 CNS Diseases
9.10.2 Gastrointestinal Diseases
9.10.3 CVS Diseases
9.10.4 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Rapid-dissolving Tablets Analysis and Forecast
10.1 Introduction
10.2 Europe Rapid-dissolving Tablets Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Rapid-dissolving Tablets Market Size Forecast by Type
10.6.1 Anti-Psychotics Drug
10.6.2 Anti-Epileptics Drug
10.6.3 Other
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Rapid-dissolving Tablets Market Size Forecast by Applications
10.10.1 CNS Diseases
10.10.2 Gastrointestinal Diseases
10.10.3 CVS Diseases
10.10.4 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Rapid-dissolving Tablets Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Rapid-dissolving Tablets Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Rapid-dissolving Tablets Market Size Forecast by Type
11.6.1 Anti-Psychotics Drug
11.6.2 Anti-Epileptics Drug
11.6.3 Other
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Rapid-dissolving Tablets Market Size Forecast by Applications
11.10.1 CNS Diseases
11.10.2 Gastrointestinal Diseases
11.10.3 CVS Diseases
11.10.4 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Rapid-dissolving Tablets Analysis and Forecast
12.1 Introduction
12.2 Latin America Rapid-dissolving Tablets Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Rapid-dissolving Tablets Market Size Forecast by Type
12.6.1 Anti-Psychotics Drug
12.6.2 Anti-Epileptics Drug
12.6.3 Other
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Rapid-dissolving Tablets Market Size Forecast by Applications
12.10.1 CNS Diseases
12.10.2 Gastrointestinal Diseases
12.10.3 CVS Diseases
12.10.4 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Rapid-dissolving Tablets Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Rapid-dissolving Tablets Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Rapid-dissolving Tablets Market Size Forecast by Type
13.6.1 Anti-Psychotics Drug
13.6.2 Anti-Epileptics Drug
13.6.3 Other
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Rapid-dissolving Tablets Market Size Forecast by Applications
13.10.1 CNS Diseases
13.10.2 Gastrointestinal Diseases
13.10.3 CVS Diseases
13.10.4 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Rapid-dissolving Tablets Market: Competitive Dashboard
14.2 Global Rapid-dissolving Tablets Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Teva
14.3.2 Merck
14.3.3 Mylan
14.3.4 Pfizer
14.3.5 Johnson and Johnson
14.3.6 GSK
14.3.7 Otsuka
14.3.8 Eli Lilly and Company
14.3.9 AstraZeneca
14.3.10 Bristol-Myers Squibb
14.3.11 Teva